Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1253/circj.CJ-22-0146 | DOI Listing |
Publication Analysis
Top Keywords
jcs/jhrs guideline
4
guideline rivaroxaban
4
rivaroxaban recommended
4
recommended patients
4
patients nonvalvular
4
nonvalvular atrial
4
atrial fibrillation
4
fibrillation high
4
high bleeding
4
bleeding risk
4
Similar Publications
Risk Factors for Treatment Transition in Patients with Low-Risk Atrial Fibrillation Patients Undergoing Anticoagulation Monotherapy: A Large Claims Database Study in Japan.
Biol Pharm Bull
July 2024
Department of Hospital Pharmaceutics, School of Pharmacy, Showa University.
The global prevalence of atrial fibrillation (AF) is rising, paralleling increased life expectancy. Early rhythm control benefits AF management. However, in low-risk, often asymptomatic, AF patients, anticoagulant monotherapy is the selected treatment, aligning with current guidelines.
View Article and Find Full Text PDFJCS/JHRS 2022 Guideline on Diagnosis and Risk Assessment of Arrhythmia.
Circ J
August 2024
Department of Pediatric Cardiology, Saitama Medical University International Medical Center.
JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk - Reply.
Circ J
June 2022
Department of Cardiovascular Medicine, Nippon Medical School.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!